High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Bone Marrow Transplantation

• Publication date

  1997-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bmt.1700820PMID 9208111
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor.

  1997cited by this paper
• Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses

  1997cited by this paper
• High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer.

  1996cited by this paper
• Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.

  1996cited by this paper
• Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer.

  1995cited by this paper
• Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.

  1995cited by this paper
• Factors that influence collection and engraftment of autologous peripheral-blood stem cells.

  1995cited by this paper
• High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.

  1995cited by this paper
• High-dose chemotherapy and autologous stem cell transplantation for breast cancer.

  1995cited by this paper
• Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation.

  1994cited by this paper
• Factors predicting long‐term survival for metastatic breast cancer patients treated with high‐dose chemotherapy and bone marrow support

  1994cited by this paper
• Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease

  1994cited by this paper
• Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.

  1994cited by this paper
• Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.

  1994cited by this paper
• Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor.

  1993cited by this paper
• Dose intensive therapy in breast cancer.

  1992cited by this paper
• High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report.

  1992cited by this paper
• A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.

  1992cited by this paper
• High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer.

  1991cited by this paper
• Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support.

  1990cited by this paper
• Regimen-related toxicity in patients undergoing bone marrow transplantation.

  1988cited by this paper
• High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.

  1988cited by this paper
• High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer.

  1987cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma

  2014cites this paper
• Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

  2013cites this paper
• Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma

  2010cites this paper
• Interleukin-2 and granulocyte–macrophage–colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer

  2009cites this paper
• High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer

  2009cites this paper
• astrointestinal Graft-versus-Host Disease in ecipients of Autologous Hematopoietic Stem Cells: ncidence, Risk Factors, and Outcome

  2006cites this paper
• Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome.

  2006cites this paper
• Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.

  2005cites this paper
• Improved assay for determination of busulfan by liquid chromatography using postcolumn photolysis.

  2004cites this paper
• Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.

  2004cites this paper
• The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).

  2003cites this paper
• Treatment of multiple myeloma.

  2003cites this paper
• A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch

  2003cites this paper
• Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation.

  2003cites this paper
• High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation

  2003cites this paper
• Traitement du myélome multiple

  2003cites this paper
• Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome.

  2002cites this paper
• Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents.

  2002cites this paper
• Treatment of Breast Cancer with Chemotherapy in Combination with Filgrastim

  2002cites this paper
• Methodologic guidelines for the design of high-dose chemotherapy regimens.

  2001cites this paper
• Fatal upper and lower gastrointestinal cytomegalovirus disease following autologous peripheral blood stem cell transplantation

  2001cites this paper
• Fatal upper and lower gastrointestinal cytomegalovirus disease following autologous peripheral blood stem cell transplantation.

  2001cites this paper
• High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer

  2000cites this paper
• High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome

  2000cites this paper
• Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine

  2000cites this paper
• Breast cancer: a guide for fellows.

  1999cites this paper
• A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.

  1999cites this paper
• The role of busulfan in bone marrow transplantation

  1999cites this paper
• Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer.

  1999cites this paper
• Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer.

  1999cites this paper
• High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors.

  1998cites this paper
• High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer

  1998cites this paper
• Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: outpatient administration in community cancer centers.

  1998cites this paper
• The Rationale for Performing Autologous Peripheral Blood Stem Cell Transplants in Community Cancer Centers.

  1998cites this paper
• Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system

  1998cites this paper